about
Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters FunctionA Study of Human Killer Cell Immunoglobulin-Like Receptor and Multidrug Resistance Gene Polymorphisms in Children With Immune Thrombocytopenia.Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results.Modulation of p-glycoprotein transport function at the blood-brain barrier.Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control.MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patientsThe impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.Nature and uses of fluorescent dyes for drug transporter studies.Inflammation and pharmacokinetics: potential implications for HIV-infection.Multiple resistance to carcinogens and xenobiotics: P-glycoproteins as universal detoxifiers.Association between ABCB1 (MDR1) gene 3435 C>T polymorphism and colchicine unresponsiveness of FMF patients.Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis.Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus.Cyclosporin rapidly diminished a severe lupus-associated macrophage association syndrome refractory to pulsed methylprednisolone and intravenous immunoglobulin.ABCB1 polymorphisms and steroid treatment in children with idiopathic nephrotic syndrome.Suppressive potencies of calcineurin inhibitors against the mitogen-induced blastogenesis of peripheral-blood mononuclear cells of myasthenia gravis patients.Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus.
P2860
Q28552801-85FCE2BA-5FA2-4E20-B745-809259AD7B6BQ33421329-DEED609F-C57F-421F-BB5B-D4B126D899C3Q34060256-2C5EE0B2-3A45-4096-A483-F6DFD57ADBC5Q34959857-018732E9-042F-46CD-9337-133E871F7E71Q36021258-D5DF397C-70D2-4F8D-81BE-6B81F9EADA90Q36409293-D74DB25E-675B-4F20-A59E-454096C4F900Q36417085-65DF0BD0-4A32-402F-A89B-5AFDCCD4C98AQ37230649-65F77164-40CB-4F70-8912-3ABEFF36B093Q37964754-FAFCB492-E694-4291-97C6-FAA53C9281AEQ38518912-323476DF-A667-45CD-BFAF-17559D898A3FQ38740792-80E0EF7B-45FD-427F-9248-A0FD04387693Q39125345-89BDD110-8B1E-4728-8C76-E465FC58AEDAQ40314857-350865A8-4B55-4F8F-8446-3764EACC579AQ41163946-17B089D2-4FB4-474E-ABE3-BFB194F017B7Q41916743-EA128B94-D046-4CEF-AF65-6AEB0C1F1850Q43239645-0FB7CBB3-52C6-4035-8EF2-5D264E24D7CCQ46225257-C8936453-FB5C-4F49-B163-37354402383CQ46351152-74C5E4E5-CA38-4BEC-ACB4-E78F788A085CQ47845373-5C8477C8-5AE9-404A-8BA1-72E5E6F71C51
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
P-glycoprotein in autoimmune diseases.
@ast
P-glycoprotein in autoimmune diseases.
@en
type
label
P-glycoprotein in autoimmune diseases.
@ast
P-glycoprotein in autoimmune diseases.
@en
prefLabel
P-glycoprotein in autoimmune diseases.
@ast
P-glycoprotein in autoimmune diseases.
@en
P2093
P1433
P1476
P-glycoprotein in autoimmune diseases.
@en
P2093
Elena Soto-Vega
Juan Jakez-Ocampo
Luis Llorente
Yvonne Richaud-Patin
P304
P356
10.1016/J.AUTREV.2003.08.002
P577
2004-03-01T00:00:00Z